For Cohorts A and B, intravesical cretostimogene will be instilled in combination with DDM, an excipient that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by ...

The first 24 patients who received treatment with cretostimogene and were evaluated for high-grade recurrence-free survival and safety were evaluated. Kaplan-Meier estimates at 3- and 9-month ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October ...

Cretostimogene grenadenorepvec, an oncolytic immunotherapy, selectively replicates in and lyses cancer cells with Rb-E2F pathway alterations, releasing antigens that initiate antitumor immune ...

Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma ...

KLK2 protein is overexpressed in prostate cancer tissue compared to benign prostate tissue and has been associated with stage ...

At the ESMO 2025 annual meeting, Dr. Hansen and colleagues presented the first-in-human data of 212 Pb-ADVC001 in patients with mCRPC from the TheraPb trial.

Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany, was host to the ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Johann S. De Bono discussing emerging new therapeutic strategies for ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a ...